Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

Median overall survival of 21.7 months in patients given two cycles of chemotherapy

Among the 319 patients who received nivolumab and ipilimumab together with chemotherapy, median real-world progression-free survival was 6.8 months. The 226 patients treated with the antibody doublet alone had a median overall survival of 18.8 months and a median real-world progression-free survival of 6.3 months. Both overall survival medians are longer than the median follow-up of 15.1 months, so they are likely to move as the cohort matures.

Real-world progression-free survival is taken from routine clinical assessments, without the fixed imaging schedule of a registration trial, which makes it a looser endpoint than the progression-free survival reported in CheckMate 9LA or CheckMate 227. The cohorts were also not randomised. Patients who received chemotherapy may have differed from those who did not in ways that a comparison of medians cannot adjust for, so the 2.9-month difference in median overall survival is not an estimate of what chemotherapy adds.

A cohort with a median age of 70, treated outside a trial

LIGHT-NING enrols patients with stage IV or recurrent NSCLC who start nivolumab plus ipilimumab in routine care, and it is ongoing. The 545 patients in this update had a median age of 70 years, 18.9% were women, and 89.9% had an Eastern Cooperative Oncology Group performance status of 0 or 1.

The combination is approved in Japan on the basis of CheckMate 9LA, which added two cycles of chemotherapy, and CheckMate 227, which did not. The authors set out to address what they describe as limited long-term real-world data in Japanese patients. The chemotherapy-containing regimen was given to 58.5% of the cohort, and the abstract does not give the reasons for that choice or set out how the two groups differed at baseline.

Grade 3 to 5 treatment-related adverse events in 53.3% with chemotherapy and 30.5% without

In absolute numbers, 170 of the 319 patients given the chemotherapy-containing regimen and 69 of the 226 given the doublet alone had a treatment-related adverse event of grade 3 or higher. The authors observed no new safety signals and describe the combination as generally manageable.

The abstract does not break these events down by type, by organ system or by the number of grade 5 events, and it does not report how many patients stopped treatment because of toxicity.

Early progression without chemotherapy tracked BMI in squamous disease and LIPI in non-squamous disease

The associations with early progressive disease were reported in the 226 patients treated without chemotherapy, separately by histology. In squamous cell carcinoma, early progression was associated with body mass index. In non-squamous disease, it was associated with serum albumin, lactate dehydrogenase and the lung immune prognostic index, a score built from the derived neutrophil-to-lymphocyte ratio and lactate dehydrogenase.

The abstract does not define early progressive disease, give its frequency, or state the direction and size of each association. The authors describe these analyses as hypothesis-generating. They would need confirmation in an independent cohort before any of the four factors could inform the choice between the two regimens.

“This analysis of LIGHT-NING study indicated that safety and effectiveness in Japanese patients were consistent with those observed in CheckMate 9LA and CheckMate 227.”Imai et al., Clinical Lung Cancer (2026)

Consistency with CheckMate 9LA and CheckMate 227, judged against randomised trial populations

The authors judge both effectiveness and safety in the Japanese cohort consistent with the two registration trials, and the abstract does not say how that consistency was assessed or print the trial figures next to its own. The trials were randomised and international, and LIGHT-NING is an observational cohort from one country, so the agreement the authors describe sets two different kinds of evidence side by side.

For clinicians in Japan, the update supplies local data collected between November 2020 and June 2024 on a regimen approved on trial evidence. The comparison between the two regimens and the factors associated with early progression remain questions for prospective study.